title: [Anti-angiogenic drugs].
abstract: Angiogenesis, the formation of neo-vessels, is a physiological event but is involved in various pathological conditions including cancers. Thus, the establishment of effective anti-angiogenic treatment has long been a goal. The recent development of bevacizumab, a neutralizing monoclonal antibody against VEGF, as the first anti-angiogenic drug, validated the clinical benefit of the inhibition of tumor angiogenesis. Thereafter, various drugs targeting VEGF-mediated signals have been developed to control tumor angiogenesis. Anti-angiogenic therapy is now considered a major step forward in cancer treatment at the clinical level.
authors.affiliation: Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Japan.
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Sato
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D042461:Vascular Endothelial Growth Factor A